title: Sodium Tanshinone IIA Sulfonate Attenuates Scopolamine-Induced Cognitive Dysfunctions via Improving Cholinergic System.
abstract: Sodium Tanshinone IIA sulfonate (STS) is a derivative of Tanshinone IIA (Tan IIA). Tan IIA has been reported to possess neuroprotective effects against Alzheimer's disease (AD). However, whether STS possesses effect on AD remains unclear. This study aims to estimate whether STS could protect against scopolamine- (SCOP-) induced learning and memory deficit in Kunming mice. Morris water maze results showed that oral administration of STS (10 mg/kg and 20 mg/kg) and Donepezil shortened escape latency, increased crossing times of the original position of the platform, and increased the time spent in the target quadrant. STS decreased the activity of acetylcholinesterase (AChE) and increased the activity of choline acetyltransferase (ChAT) in the hippocampus and cortex of SCOP-treated mice. Oxidative stress results showed that STS increased the activity of superoxide dismutase (SOD) and decreased the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) in hippocampus and cortex. In addition, western blot was carried out to detect the expression of apoptosis related proteins (Bcl-2, Bax, and Caspase-3). STS upregulated the protein expression of Bcl-2 and downregulated the proteins expression of Bax and Caspase-3. These results indicated that STS might become a promising therapeutic candidate for attenuating AD-like pathological dysfunction.
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Qing-Qing
authors.identifier: 0000-0002-3920-3556
authors.initials: QQ
authors.lastname: Xu
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Yi-Jun
authors.initials: YJ
authors.lastname: Xu
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Cong
authors.initials: C
authors.lastname: Yang
authors.affiliation: The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Ying
authors.identifier: 0000-0001-5666-8139
authors.initials: Y
authors.lastname: Tang
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Li
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Hao-Bin
authors.identifier: 0000-0001-6917-1850
authors.initials: HB
authors.lastname: Cai
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Bo-Nan
authors.initials: BN
authors.lastname: Hou
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Hui-Fang
authors.initials: HF
authors.lastname: Chen
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Wang
authors.affiliation: School of Chinese Materia Medica, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Xu-Guang
authors.identifier: 0000-0003-2437-6400
authors.initials: XG
authors.lastname: Shi
authors.affiliation: Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
authors.forename: Shi-Jie
authors.identifier: 0000-0001-5399-7260
authors.initials: SJ
authors.lastname: Zhang
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D060825:Cognitive Dysfunction / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D006624:Hippocampus / Q000187:drug effects / Q000473:pathology; D006801:Humans; D007859:Learning Disabilities / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D018782:Maze Learning / Q000187:drug effects; D051379:Mice; D000070634:Non-Neuronal Cholinergic System / Q000187:drug effects*; D018384:Oxidative Stress / Q000187:drug effects; D010616:Phenanthrenes / Q000008:administration & dosage* / Q000737:chemistry; D012601:Scopolamine / Q000633:toxicity
chemical_list: D010616:Phenanthrenes; C024894:tanshinone II A sodium sulfonate; D012601:Scopolamine